Agnès Lillo Le Louet

Safety of immune checkpoint inhibitor rechallenge and mid-term outcomes after suspected cardiovascular immune-related adverse events

Abstract Background Current European Society of cardiology guidelines recommend systematic troponin screening to detect potential cardiovascular (CV) immune-related adverse events (irAEs) in the increasing numbers of cancer patients receiving immune-checkpoint inhibitors (ICIs),...